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Abstract  30 
Background: Small cell lung cancer (SCLC) is an aggressive cancer often presenting in an advanced stage 31 
and prognosis is poor. Early response evaluation may have impact on the treatment strategy.  32 
Aim: We evaluated 18F-fluorothymidine-(FLT)-PET/diffusion-weighted-(DW)-MRI early after treatment start 33 
to describe biological changes during therapy, the potential of early response e valuation and the added 34 
value of FLT-PET/DW-MRI. 35 
Methods: Patients with SCLC referred for standard chemotherapy were eligible. FLT-PET/DW-MRI of the 36 
chest and brain was acquired within 14 days after treatment start. FLT-PET/DW-MRI was compared with 37 
pretreatment FDG-PET/CT. Standardized uptake value (SUV), apparent diffusion coefficient (ADC) and 38 
functional tumor volumes were measured. FDG-SUVpeak, FLT-SUVpeak and ADCmedian; spatial distribution of 39 
aggressive areas; and voxel-by-voxel analyses were evaluated to compare the biological information 40 
derived from the three functional imaging modalities. FDG-SUVpeak, FLT-SUVpeak and ADCmedian were also 41 
analyzed for ability to predict final treatment response. 42 
Results: Twelve patients with SCLC completed FLT-PET/MRI 1–9 days after treatment start. In nine patients, 43 
pretreatment FDG-PET/CT was available for comparison. A total of 16 T-sites and 12 N-sites were identified. 44 
No brain metastases were detected.  45 
FDG-SUVpeak was 2.0–22.7 in T-sites and 5.5–17.3 in N-sites. FLT-SUVpeak was 0.6–11.5 in T-sites and 1.2–2.4 46 
in N-sites. ADCmedian was 0.76–1.74 x10-3 mm2/s in T-sites and 0.88–2.09 x10-3 mm2/s in N-sites.  47 
FLT-SUVpeak correlated with FDG-SUVpeak, and voxel-by-voxel correlation was positive, though the hottest 48 
regions were dissimilarly distributed in FLT-PET compared to FDG-PET.  49 
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FLT-SUVpeak was not correlated with ADCmedian, and voxel-by-voxel analyses and spatial distribution of 50 
aggressive areas varied with no systematic relation. 51 
FLT-SUVpeak was significantly lower in responding lesions than non-responding lesions (mean FLT-SUVpeak in 52 
T-sites: 1.5 vs. 5.7; p=0.007, mean FLT-SUVpeak in N-sites: 1.6 vs. 2.2; p=0.013).  53 
Conclusions: FLT-PET and DW-MRI performed early after treatment start may add biological information in 54 
patients with SCLC. Proliferation early after treatment start measured by FLT-PET is a promising predictor 55 
for final treatment response that warrants further investigation. 56 
 57 
Trial registration: clinicaltrials.gov, NCT02995902. Registered 11 December 2014 - Retrospectively 58 
registered, https://clinicaltrials.gov/ct2/show/NCT02995902?term=NCT02995902&rank=1 59 
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Introduction 69 
Functional imaging, as positron emission tomography (PET) and diffusion-weighted magnetic resonance 70 
imaging (DW-MRI), are important tools to gain non-invasive information about tumor biology and tumor 71 
heterogeneity. 18F-fluorodeoxy-glucose (FDG)-PET/CT has established its role in staging of small cell lung 72 
cancer (SCLC) (1) and causes stage migration in up to 40% of the patients influencing the choice of 73 
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treatment and outcome (2). FDG-PET has shown prognostic value in SCLC (3-10), but the potential of FDG-74 
PET for early response evaluation remains unclear (11, 12). 75 
SCLC is an aggressive cancer with more than 2/3 of the patients presenting in stage IV (13).  Over the last 76 
three decades, improvements for patients with SCLC have been sparse . However recently, new drug classes 77 
including immune check point inhibitors (14, 15) and transcription inhibitors (16) have raised hope for 78 
improving the treatment results. Accordingly, the need for a better understanding of tumor biology and 79 
prognostication is higher than ever.  80 
18F-fluorothymidine (FLT) is a PET-tracer of proliferation (17, 18). FLT-PET has been studied in SCLC 81 
xenografts in mice showing promise for early response evaluation of treatment with epidermal growth 82 
factor receptor tyrosine kinase inhibitors (EGFR TKI) (19), but we are unaware of any studies of FLT-PET in 83 
patients with SCLC. In patients with non-small cell lung cancer (NSCLC), pretreatment FLT-PET/CT and FLT-84 
PET/CT early after treatment start has shown prognostic value (17, 18, 20-22). Early response evaluation 85 
measured by FLT-PET/CT was prognostic for progression free survival (PFS) in patients with NSCLC treated 86 
with EGFR TKI (23-25). Results from patients treated with a platin-based chemotherapy (26) and concurrent 87 
chemo-radiotherapy were, however, non-significant (22, 27). In contrary to FDG, FLT does not cross the 88 
blood-brain barrier if intact (28). FLT-PET is however able to detect brain tumors (28) and brain metastases 89 
(29-32) possible due to disruption of the blood brain-barrier in these patients. 90 
DW-MRI measures water diffusion within the tissue which is affected by micro textural features. Tumors 91 
with a high cell density and a poor differentiation have restricted water diffusion, which can be quantified 92 
by a lower apparent diffusion coefficient (ADC) (33). A meta-analysis has shown that ADC can distinguish 93 
malignant lesions in the lungs from benign lesions and that ADC is lower in SCLC than NSCLC (34). ADC 94 
change after therapy has proven prognostic of overall survival (OS) in a study mixed of patients with SCLC 95 
and NSCLC (35). Other studies of patients with NSCLC have confirmed predictive and prognostic value of 96 
ADC change during therapy (33, 36, 37), though baseline ADC did not show prognostic value (20, 37).  97 
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The objectives of this study were to pilot the potential of FLT-PET and DWI-MRI early after treatment start 98 
in patients with SCLC; for early evaluation of tumor biology during treatment and for early response 99 
evaluation. 100 
To our knowledge, this is the first study to examine FLT-PET in patients with SCLC. 101 
 102 
 103 
Methods 104 
Patients: 105 
Patients with histologically verified SCLC, referred to first line standard chemotherapy, and patients with 106 
relapsed SCLC referred to reinduction of standard chemotherapy, were eligible. Patients were recruited at 107 
Dept. of Oncology, Rigshospitalet, Denmark from November 2014 to May 2017. All patients gave informed 108 
consent, and the study was approved by the local ethics committee , approval number H-1-2014-026.  109 
 110 
 111 
Imaging: FLT-PET/MRI was performed within 14 days after start of chemotherapy on an integrated 112 
PET/MRI system (Siemens Biograph mMR) with a 3-T magnet. FLT (5 MBq/kg, max 350 MBq) was injected 113 
60 minutes prior to PET/MRI, without restrictions regarding fasting or resting. PET and MRI were conducted 114 
simultaneously as static, regional images starting with one bed position over cerebrum followed by one bed 115 
position over thorax centered on the primary tumor. T1-weighted imaging with and without gadolinium 116 
contrast, T2-weighted imaging, and DWI were acquired over both bed positions using the following 117 
protocol:  118 
Cerebrum: 3D VIBE for PET attenuation correction (echo time (TE) 4.00 ms; repetition time (TR) 8.6 ms; 119 
voxel size 1.1x1.0x7.0 mm3); sagittal T1 MPRAGE (TE 2.44 ms; TR 1900 ms; voxel size 1.0x1.0x1.0 mm3); 120 
transverse T2 BLADE (TE 117 ms; TR 5550 ms; voxel size 0.7x0.7x5.0 mm3); DWI using single-shot Echo-121 
Planar Imaging (EPI) (TE 101 ms; TR 6800 ms; voxel size 1.1x1.1x4.0 mm3, b-values of 0 and 800 s/mm2). 122 
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Thorax: 3D VIBE for PET attenuation correction (TE 1.23/2.46 ms; TR 3.60 ms; voxel size 4.1x2.6x3.1 mm3); 123 
transverse T1 VIBE in breath-hold (TE 1.23 ms; TR 3.46 ms; voxel size 1.7x1.3x4.0 mm3); DWI using single-124 
shot EPI triggered to the position of the diaphragm (TE 73 ms; TR 2200 ms; voxel size 3.7x3.0x5.0 mm3; b-125 
values of 0, 150, 400 and 800 s/mm2); coronal T2 BLADE in four breath-holds with Gadolinium-based 126 
contrast (TE 138 ms; TR 2030 ms; voxel size 1.4x1.4x6.0 mm3); transverse T1 VIBE in breath-hold employing 127 
a small shim volume covering the tumor, with Gadolinium-based contrast (TE 1.23 ms; TR 3.46 ms; voxel 128 
size 1.7x1.3x4.0 mm3). Cerebrum: sagittal T1 MPRAGE with Gadolinium-based contrast (TE 2.44 ms; TR 129 
1900 ms; voxel size 1.0x1.0x1.0 mm3). 130 
FLT-PET data were reconstructed using Ordinary Poisson 3D Ordered Subset Expectation Maximization (OP-131 
OSEM) with 3 iterations, 21 subsets, voxel size 2.1x2.1x2.0 mm3 with Siemens standard MR-based Dixon 132 
attenuation correction and 4 mm post-filtering. 133 
If pretreatment FDG-PET/CT had been performed, this was included in the study. Pretreatment FDG-PET/CT 134 
was at different hospitals by clinical indication. Accordingly, pretreatment FDG-PET/CT was performed on 135 
different scanner models and variant PET-protocols (details available in supplementary Table 1). 136 
 137 
Image analysis: 138 
All imaging datasets were analyzed on a Mirada Medical Ltd XD 3.6 workstation (MIRADA Medical, Oxford, 139 
UK). 140 
Metabolic tumor volume (MTV) was delineated on pretreatment FDG-PETs by thresholds of 41% and 50% 141 
of maximum standardized uptake value (SUVmax) (MTV41 and MTV50), as recommended by the European 142 
Association of Nuclear Medicine (EANM) procedure guidelines (38). 143 
Proliferative tumor volume (PTV) being the functional tumor volume by FLT-PET (equivalent to MTV by 144 
FDG-PET), was delineated on posttreatment FLT-PETs using the same thresholds as recommended for FDG-145 
PET (PTV41 and PTV50) as well as with an absolute threshold of SUV=1.4 (PTV1.4), as recommended by 146 
Thureau et al (39). Within the above tumor volumes; volume, SUVmax, SUVpeak, and SUVmean were measured. 147 
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Total lesion glycolysis (TLG) by FDG-PET and total lesion proliferation (TLP) by FLT-PET were calculated by 148 
multiplying MTV and PTV with the corresponding SUV mean (e.g. TLG41 = MTV41 x SUVmean41; TLP50 = PTV50 149 
x SUVmean50) for each tumor volume. 150 
Diffusion-weighted tumor volume (DWTV25) was delineated on DW-MRIs (b=800 s/mm2) using a threshold 151 
of 25% of maximum. DWTV25 was projected to the ADC-map for quantifying ADCmean and ADCmedian. 152 
In addition, volumes of the primary tumor, lymph nodes and distant metastases included in the MRI field of 153 
view were contoured by an experienced radiologist on T1-weighted MRI with gadolinium contrast, 154 
following recommendations for delineation of gross tumor volume (GTV) (40). The MRI contours were 155 
projected to FDG-PET, FLT-PET and the ADC-map for voxel-by-voxel analyses comparing the modalities. 156 
Image modalities were rigidly registered and subsequently resampled to identical voxel sizes. Voxel-by-157 
voxel analysis was considered reasonable when the measured position of lesional landmarks in registered 158 
scans deviated by less than 10 mm in the direction of maximum displacement and if visual inspection 159 
indicated good overall alignment, or in lesions with no characteristic landmarks, good overall alignment by 160 
visual inspection. If visual inspection indicated adequate overall alignment, a maximum of 5 mm in the 161 
direction of maximum displacement was considered reasonable for voxel -by-voxel analysis. 162 
Within each lesion, we spatially compared the most “aggressive” areas within the tumor defined by each 163 
scan modality. The most aggressive areas were defined as the area with highest metabolism or highest 164 
proliferation measured by FDG-PET and FLT-PET, respectively, and by DW-MRI as the areas with lowest 165 
diffusion. The most aggressive areas were delineated on FDG-PET and FLT-PET using a threshold of 70% of 166 
SUVmax (MTV70; PTV70), and on DW-MRI (b=800 s/mm2) using a threshold of 50% (DWTV50).  167 
Overlap of MTV70 vs. PTV70 and PTV70 vs. DWTV50 were analyzed visually. Overlap were graded as no 168 
overlap, partial overlap (<50% overlap), or high overlap (>50% overlap). 169 
As a quality control, FLT uptake within normal tissue was measured, as recommended by Cysouw et al . (41). 170 
Briefly, liver FLT-uptake was measured in a 3 cm in diameter sphere placed in the right upper lobe of the 171 
liver; bone marrow FLT-uptake was measured in a 1 cm in diameter sphere placed in a lower thoracic 172 
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vertebra; and FLT-uptake in the mediastinal blood pool was measured in a cylinder of 1x2 cm in ascending 173 
aorta. Metastases, previously irradiated tissue and the aortic wall were avoided. Within these volumes, FLT-174 
SUVmax, FLT-SUVpeak and FLT-SUVmean were measured. 175 
 176 
Follow up and outcome: 177 
Patients were followed until one year after the last patient had completed FLT-PET/MRI.  178 
Final response to treatment was determined by routine CT using The Response Evaluation Criteria in Solid 179 
Tumors (RECIST) 1.1 (42). 180 
Response of each lesion was defined by the same limits as used in RECIST 1.1 (response: >30% decrease of 181 
longest lesion diameter; progression: >20% increase of longest lesion diameter; no change: neither 182 
response nor progression).  183 
PFS was defined as time from PET/MRI to progression or death of any cause, whichever occurred first. OS 184 
was defined as time from PET/MRI to death of any cause. 185 
 186 
Statistics: 187 
Statistical analyses were performed in SPSS, version 25. 188 
Correlation analyses of PET-parameters and MRI-parameters across patients were performed using 189 
Spearman’s rank correlation. Within-patient voxel-by-voxel analyses were performed by linear regression. 190 
Differences of each PET- and MRI-parameter in lesions with response vs. lesions with no change or 191 
progression were tested by an independent t-test for response prediction. Levene’s test was used for test 192 
of equality of variances and if variances were not equal, data was transformed by the natural logarithm 193 
prior to the independent t-test analysis. 194 
PFS and OS were calculated using the Kaplan-Meier method.  195 
P<0.05 was considered statistically significant. 196 
 197 
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 198 
Results 199 
Patient data 200 
FLT-PET/MRI was conducted in 12 patients, but in one patient DW-MRI of thorax failed. Figure 1 provides 201 
an overview of the inclusion process. 202 
Table 1 presents the characteristics and outcome of the 12 patients. Nine patients had extensive disease 203 
(ED); one patient had limited disease (LD); and two patients had a relapse of SCLC and had previously been 204 
treated with concomitant chemo-radiotherapy. All patients were either active or former smokers with 40-205 
60 pack-years. 206 
All patients were treated with chemotherapy; 11 patients received at least three cycles of cis- or 207 
carboplatin and etoposide; one patient received only one cycle of etoposide. The patient with LD received 208 
concomitant radiotherapy (RT) to 45 Gy, and three patients with ED received sequential RT to 30 Gy; in two 209 
patients due to poor response to chemotherapy, and in one patient as consolidation treatment.  210 
Median OS was 10.5 months, and median PFS was 5.1 months. Evaluated on CT, two patients had complete 211 
response, five patients had partial response, three patients had stable disease, one patient had progressive 212 
disease, and one patient had no relevant follow up scans as he died 1.5 months after treatment start. The 213 
seven responders all had relapse within 4 months after last exposure to chemotherapy.  214 
 215 
Scan data 216 
FLT-PET/MR was performed 1–9 days after start of chemotherapy (median 4.5 days). Pretreatment FDG-217 
PET/CT was available in nine patients. FDG-PET/CT was performed 7–21 days before FLT-PET/DW-MRI 218 
(median 16 days). An overview of scan data and times is presented in supplementary Table 1. 219 
 220 
Malignant lesions: 221 
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A total of 32 lesions were analyzed; 16 T-sites, 12 N-sites, and 4 M-sites. T-, N-, and M-sites will be 222 
described separately. 223 
Table 2 provides an overview of identified lesions, selected parameters and lesion specific outcome (all 224 
PET- and MRI-parameters are available in supplementary Table 2). In many lesions, FLT-uptake was low 225 
compared with background uptake, and, accordingly, delineation of PTV was not possible in 3 of 16 T-sites 226 
and 9 of 12 N-sites. Sufficient alignment was not achieved in all lesions and voxel-by-voxel analysis for FDG-227 
PET vs. FLT-PET was feasible in only 4 T-sites, 7 N-sites and 2 M-sites. Voxel-by-voxel analyses for FLT-PET 228 
vs. DW-MRI were feasible in 9 T-sites, 9 N-sites and 2 M-sites. The alignment of FDG-PET and DW-MRI was 229 
generally poor, and no voxel-by-voxel analyses of FDG-PET vs. ADC were feasible.  230 
All SUVs from FDG-PET (FDG-SUVmax, FDG-SUVpeak, FDG-SUVmean41, and FDG-SUVmean50) were significantly 231 
correlated (p<0.001), as were all SUVs from FLT-PET (FLT-SUVmax, FLT-SUVpeak, FLT-SUVmean41, FLT-SUVmean50 232 
and FLT-SUVmean1.4), all ADCs (ADCmean and ADCmedian), and all tumor volumes (MTV41, MTV50, PTV41, 233 
PTV50, PTV1.4; DWTV25 and GTV). Therefore, for further evaluation only FDG-SUVpeak, FLT-SUVpeak, 234 
ADCmedian, MTV41, PTV50, DWTV25, TLG41 and TLP50 are presented. 235 
 236 
T-sites 237 
From the nine patients who had a pretreatment FDG-PET/CT, all T-sites (n=13) were detectable by FDG-PET. 238 
FDG-SUVpeak varied from 2.0–22.7. 239 
All patients completed FLT-PET, but from the 16 T-sites, only five T-sites had an FLT-uptake clearly 240 
distinguishable from background. These five T-sites had a heterogeneous FLT-uptake and only a fraction of 241 
the tumor had a highly visible FLT-uptake. FLT-SUVpeak from the 16 T-sites varied from 0.6–11.5. 242 
From the 11 patients whom completed DW-MRI, 12 of 15 T-sites were detectable by DW-MRI, and 243 
ADCmedian varied from 0.76–1.74 x10-3 mm2/s. Another three T-sites had no signal on DW-MRI: on 244 
pretreatment FDG-PET/CT, these were all small with a diameter of maximum 1.6 cm. 245 
11 
 
In each lesion, FLT-SUVpeak was lower than FDG-SUVpeak. FDG-SUVpeak and FLT-SUVpeak were significantly 246 
correlated (p=0.018), as shown in Figure 2a. ADCmedian was not significantly correlated with FDG-SUVpeak or 247 
FLT-SUVpeak, as shown in Figure 2b-c. 248 
Due to low FLT-uptake, limited spatial information was available in many lesions. Accordingly, comparison 249 
of the most “aggressive” regions on FDG-PET and FLT-PET were possible only in three T-sites. Within these 250 
three T-sites, the “aggressive” regions were distributed unevenly and there was no overlap of MTV70 and 251 
PTV70.  252 
Voxel-by-voxel analysis comparing FDG-PET vs. FLT-PET was feasible in four T-sites. In three of four lesions, 253 
the overall voxel-by-voxel correlation of FDG-PET and FLT-PET was moderate (r=0.49–0.50), but the voxels 254 
with highest FLT-uptake were randomly distributed along the FDG-uptake-scale, confirming that the overall 255 
correlation is not applicable for the hottest voxels. The fourth voxel-by-voxel analysis showed a weak 256 
correlation.  257 
Comparison of the most “aggressive” regions of FLT-PET and DW-MRI was possible in four T-sites: Two T-258 
sites had a partial overlap of PTV70 and DWTV50, and two T-sites had no overlap of PTV70 and DWTV50. 259 
There was no systematic correlation on the voxel-by-voxel analysis of FLT-PET and ADC (r= -0.66 to 0.42, 260 
n=9). 261 
Figures 3 and 4 are examples of two representative T-sites with high, respectively, low FLT-uptake. As 262 
illustrated by Figures 3 and 4, the three imaging modalities show apparently different patterns of intra-263 
tumor heterogeneity. 264 
 265 
N-sites 266 
The 12 N-sites each consisted of a single lymph node or larger lymph node conglomerates, and therefore 267 
varied substantially in size (GTV: 3.9–119.7 cm3). 268 
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FDG-SUVpeak ranged from 5.5 to 17.3. FLT-uptake was distinguishable from background uptake only in three 269 
of 12 N-sites, all in the same patient. FLT-SUVpeak ranged from 1.2 to 2.4. ADCmedian ranged from 0.88–2.09 270 
x10-3 mm2/s. 271 
In each N-site, FLT-SUVpeak was lower than FDG-SUVpeak, and their correlation was significant (p=0.038), see 272 
Figure 2d. ADCmedian correlated negative with FDG-SUVpeak (p=0.006), but there was no significant 273 
correlation between ADCmedian and FLT-SUVpeak, as illustrated in Figure 2e-f. 274 
Spatial comparisons were possible only in the three N-sites, due to the low detection rate by FLT-PET. 275 
MTV70 and PTV70 showed partial or high overlap in all three N-sites, and voxel-by-voxel correlations of 276 
FDG-PET and FLT-PET was moderate and positive (r=0.41–0.60). PTV70 and DWTV50 showed partial or high 277 
overlap, and voxel-by-voxel correlations of FLT-PET and ADC were weak and negative (r= -0.44 to -0.15). 278 
Figure 5 illustrates an N-site that could be visualized by all three imaging modalities. As illustrated with this 279 
N-site, but applicable for all three N-sites that were detectable by all three imaging modalities, the most 280 
“aggressive” regions showed partial or high overlap, but most lesions were undetectable by FLT-PET. 281 
 282 
M-sites: 283 
No brain metastases were detected by FDG-PET, FLT-PET, DW-MRI or MRI. 284 
M-sites were detected in the lung, in an axillary lymph node, two in subcutis, two in bones (vertebras) and 285 
several in the liver. Parameters from the four metastases in the lung, axilla and subcutis are available in 286 
Table 2, but due to the small number and the heterogeneity of localization, no further analyses were 287 
conducted. 288 
 289 
Prediction of final response to treatment:  290 
Of the 28 T- and N-sites, 20 responded to chemotherapy: three T-sites had no change and three N-sites 291 
progressed during chemotherapy. Another two lesions were not response evaluated; One because the 292 
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patients died prior to evaluation (7-T); and one because it was incorporated in atelectasis and not evaluable 293 
after 6 cycles (11-T2).  294 
No T-sites progressed during chemotherapy, and no N-sites had no change, therefore comparing analyses 295 
were performed of T-sites with response vs. no change; and N-sites with response vs. progression. 296 
MTV41, TLG41, FLT-SUVpeak and TLP50 were significantly lower in T-sites with response than T-sites with no 297 
change (mean MTV41: 41 vs. 208 cm3; p=0.002; mean TLG41: 311 vs. 2410; p=0.006; mean FLT-SUVpeak: 1.5 298 
vs. 5.7; p=0.007; mean TLP50: 35.5 vs 120.5; p=0.029). In N-sites, FLT-SUVpeak was significantly lower in 299 
responding N-sites than N-sites with progression (mean FLT-SUVpeak 1.6 vs 2.2; p=0.013).  300 
FDG-SUVpeak, TLG41, PTV50, ADCmedian and DWTV did not show any difference in responding vs. no change 301 
T-sites, or progressing N-sites, neither did MTV41 and TLP50 from N-sites.  302 
The differences of FDG-SUVpeak, FLT-SUVpeak and ADCmedian in responding vs. no change or progressive lesions 303 
are illustrated in Figure 6. As seen in Figure 6b, FLT-SUVpeak was lower in all, but one responding T-site (FLT-304 
SUVpeak 0.6 – 2.8) compared with T-sites with no change (FLT-SUVpeak 2.6 – 11.5).  305 
All comparing analyses are available in supplementary Table 3. 306 
 307 
FLT uptake in normal tissue 308 
FLT-uptake in normal tissue showed large variation across the patients. Liver FLT-SUVpeak ranged from 2.0–309 
11.3 (reference: 3.46–7.46); blood pool FLT-SUVpeak ranged from 0.6–1.3 (reference: 0.44–1.04); and bone 310 
marrow FLT-SUVpeak ranged from 1.2–11.3 (reference: 4.86–11.36), reference values from (41). There were 311 
no significant correlations between normal tissue FLT-uptake and time from treatment start to FLT-312 
PET/MRI or FLT-uptake time. FLT-SUV in the liver, blood pool and bone marrow are available in 313 
supplementary Table 4. In most cases, FLT-uptake in normal tissue was not within Cysouw’s reference 314 
interval (41). In particular, bone marrow FLT-uptake was lower than the reference interval in 10 of 12 315 
patients. Three patients had a lower liver FLT-uptake compared with the reference interval, and two 316 
patients had higher liver and blood pool FLT-uptake compared with the reference interval. 317 
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 318 
 319 
Discussion: 320 
The aim of this study was to perform a pilot study of the potential of FLT-PET and DW-MRI early after 321 
treatment start in patients with small cell lung cancer. Our study indicates that FLT-PET and DW-MRI after 322 
one cycle of chemotherapy has a potential to add biological information to pretreatment FDG-PET, as the 323 
most proliferative active regions measured by FLT-PET, the most water diffusion restricted regions 324 
measured by DW-MRI and the most metabolically active regions measured by FDG-PET were all dissimilarly 325 
distributed.  326 
We showed that persistent proliferation measured by FLT-PET 1–9 days after start of chemotherapy is a 327 
potential predictor of non-response to treatment, whereas, the value of DW-MRI early after treatment 328 
start was unconvincing as ADC was not associated with final response.  329 
The secondary aim of our study was to examine the added value of FLT-PET/DW-MRI in detection of brain 330 
metastases from SCLC. Unfortunately, we were not able clarify this issue, as none of the included patients 331 
had brain metastases. 332 
 333 
It has previously been reported that up to 40% of patients with ED SCLC do not achieve objective response 334 
to first line therapy (43), therefore early response evaluation to identify non-responders may have great 335 
impact. CT-response after the first cycle of chemotherapy in patients with LD SCLC has shown prognostic 336 
value of PFS and OS (44-46), but whether early CT-response can predict final treatment response has not 337 
been addressed, and patients with ED were not included in these studies (44-46). FDG-PET/CT has shown 338 
potential of early response evaluation in two studies (11, 12), but each study identified only one non-339 
responder, therefore the ability to discriminated between responders and non-responders were less 340 
powerful. In the present study, we showed that FLT-PET early after treatment start has a potential to 341 
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predict final response. A cut-off was not established, but the overlap of FLT-SUVpeak in responding vs. non-342 
responding lesions was small. 343 
We did not find any potential value of DW-MRI early after treatment start in patients with SCLC. DW-MRI 344 
has only been investigated sparsely in patients with SCLC after treatment start. Tsuchida et al. (35) included 345 
11 patients with SCLC in a study of a mixed lung cancer cohort: ADC after treatment in patients with SCLC 346 
was similar to our results: 0.91–1.97 x10-3 mm2/s, and absolute ADC after treatment was not associated 347 
with final response or OS. The change of ADC from baseline to early after treatment has shown predictive 348 
and prognostic value in patients with NSCLC (33, 35-37). It seems ADC early after treatment start is less 349 
valuable than an ADC-change from baseline. The voxel-by-voxel correlations of FDG-PET, FLT-PET and ADC 350 
were overall weak. Uncertainties of the intermodal image registration and varying respiration management 351 
strategies could potentially influence the voxel-by-voxel analysis. However, in consistence with the 352 
spatiovisual analysis, the results of the voxel-by-voxel analysis showed a dissimilar and heterogeneous 353 
distribution of the most aggressive regions of the modalities. 354 
Recruiting patients to this study proved difficult and many potentially eligible patients were not included 355 
due to poor patient condition. To investigate the risk of a selection bias, we compared blood lactate 356 
dehydrogenase (LDH) and WHO Performance Status (PS) from a cohort of eligible, but not-included patients 357 
who attended our institution during the recruiting period and found no significant differences of LDH or PS  358 
(LDH: p=0.663; PS: p=0.053). Comparing our cohort with a recently published large French retrospective 359 
study of patients with SCLC from 1997 to 2017 (43), patients in our study had a better PS (PS ≥ 2: 17% vs. 360 
44%), but more often ED (92% vs. 58%), poorer response rate (63% vs. 73%), and slightly shorter OS (10.5 361 
months vs. 12.2 months). A systematic bias in the recruiting process is therefore not obvious. 362 
This study has several technical limitations. We included pretreatment FDG-PET/CTs conducted according 363 
to varying clinical protocols of several referring hospitals; accordingly, there were several technical 364 
variations from patient to patient, and the FDG-PET parameters should be interpreted with caution. FLT-365 
PET/MRI was performed over cerebrum first and secondly over thorax, causing long FLT-uptake time before 366 
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obtaining FLT-PET of thorax. MRI artifacts may affect the SUV quantification, as described in FDG-PET/MR 367 
(47). Reproducibility of FLT-SUV quantification after MRI attenuation correction has not been established, 368 
but for FDG-PET/MRI, the reproducibility is high (48). As a FLT-PET quality control, we assessed FLT-uptake 369 
in normal tissue for comparison with previously suggested references (41). In many cases, normal tissue 370 
FLT-uptake in our patients was not comprised within the reference intervals. In particular, bone marrow 371 
FLT-uptake was lower in 10 of 12 patients, but also blood pool and liver FLT-uptake deviated from the 372 
references. The numerous outliers could have biological and/or technical explanations. Firstly, the known 373 
issue of detection of bone in Dixon MR-based attenuation (MRAC) correction may affect the measured FLT-374 
uptake in the bone marrow as it is surrounded by bone (49, 50). Secondly, the reference intervals were 375 
established from a FLT-PET with a FLT-uptake time of 60 minutes, whereas FLT-uptake time in our study 376 
was 69–84 minutes. Thirdly, the PET reconstruction variables such as choice of reconstruction method (e.g. 377 
w/o time of flight and resolution modeling), number of iterations and subsets and variations on correction 378 
methods (scatter, randoms and attenuation correction in general) can also influence  PET quantification 379 
significantly. Noise in low FLT-uptake regions such as the blood pool and bone marrow might also have 380 
considerable effect. Fourthly, Cysouw’s references was based on baseline imaging and based on patients 381 
treated with EGFR TKIs, and in this setting a slight increase in liver and bone marrow FLT-uptake after 382 
treatment was suggested. Our patients received a myelosuppresive treatment, and i t has previously been 383 
shown that FLT-uptake in the bone marrow reflects the hematopoietic activity (51). In concordance with 384 
the lower bone marrow and liver FLT-uptake in our results, Leimgruber et al. found a decrease in liver and 385 
bone marrow FLT-uptake (median 31% and 22%, respectively) two weeks after treatment with 386 
cisplatin/etoposide in a concurrent radiotherapy regimen (52). Fifthly, timing after treatment start may 387 
influence the effect of chemotherapy on normal tissue FLT-uptake. In our study, there was no significant 388 
correlation between the FLT-parameters and time from treatment start to FLT-PET/MR, but two patients in 389 
our study had FLT-PET/MRI conducted only one day after treatment start, and they both had higher FLT-390 
uptake in the liver and in the blood pool than the remaining patients and higher than the references.  391 
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It is plausible that different anticancer treatments affect proliferation in normal tissues differently, and the 392 
deviations of normal tissue FLT-uptake in this study from the references could solely originate from 393 
biologically induced changes. Despite the presence of technical limitations, we believe that the tendencies 394 
in this study are trustworthy. 395 
 396 
With the recent introduction of new treatments, there is an urgent need for larger studies to determine the 397 
diagnostic accuracy and implication of early treatment response. Preclinical studies and studies of other 398 
cancers than SCLC have shown that FLT-SUVmax reduces more rapidly and/or more pronounced than FDG-399 
SUVmax during therapy (21, 53-55), but individual treatments may affect FDG- and FLT-uptake changes 400 
differently (56), and thus should be investigated separately. In studies of NSCLC, esophagus cancer and 401 
lymphoma, early response evaluated by FLT-PET predicted final response better than FDG-PET (57-59), but 402 
it is not clear whether response by FLT-PET has superior prognostic value to FDG-PET, as results have been 403 
inconsistent (21, 24, 27). FLT-PET early after treatment start is a promising predictor for final response, but 404 
at this point it is not clear which imaging modality is most valuable. For further validating the value of FLT-405 
PET in SCLC, including baseline FLT-PET and correlating FDG-PET and FLT-PET at the same phase of 406 
treatments, would be beneficial in future studies. 407 
 408 
 409 
Conclusions:  410 
Persistent proliferation measured by FLT-PET early after treatment start was associated with poor response 411 
to chemotherapy in patients with SCLC. Thus, FLT-PET is a potential tool for selecting patients to be 412 
considered for change of treatment. We found no association between DW-MRI early after treatment and 413 
the final response. 414 
 415 
 416 
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Abbreviations: 418 
PET: positron emission tomography 419 
MRI: magnetic resonance imaging 420 
DW-MRI: diffusion-weighted magnetic resonance imaging 421 
FDG: 18F-fluorodeoxy-glucose 422 
SCLC: small cell lung cancer 423 
FLT: 18F-fluorothymidine 424 
EGFR TKI: epidermal growth factor receptor tyrosine kinase inhibitors 425 
NSCLC: non-small cell lung cancer 426 
PFS: progression free survival 427 
ADC: apparent diffusion coefficient 428 
OS: overall survival 429 
TE: Echo time 430 
TR: Repetition time 431 
EPI: Echo-Planar Imaging 432 
OP-OSEM: Ordinary Poisson 3D Ordered Subset Expectations Maximization  433 
MTV: Metabolic tumor volume. MTV41, MTV50, and MTV70: Metabolic tumor volume delineated with 434 
thresholds of 41%, 50% and 70% of SUVmax, respectively 435 
SUV: standardized uptake value. SUVmax: maximum standardized uptake value. SUVmean41, SUVmean50 and 436 
SUVmean1.4: mean of SUVs included in MTV41/PTV41, MTV50/PTV50 and PTV1.4, respectively. 437 
EANM: European Association of Nuclear Medicine  438 
PTV: Proliferative tumor volume. PTV41, PTV50, PTV1.4, PTV70: Proliferative tumor volume delineated with 439 
thresholds of 40% of SUVmax, 50% of SUVmax, SUV=1.4, and 70% of SUVmax, respectively 440 
TLG: Total lesion glycolysis  441 
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TLP: Total lesion proliferation 442 
DWTV: Diffusion-weighted tumor volume. DWTV25 and DWTV50: Diffusion-weighted tumor volume 443 
delineated with thresholds of 25% and 50% of maximum, respectively 444 
GTV: gross tumor volume 445 
RECIST: The Response Evaluation Criteria in Solid Tumors 446 
ED: extensive disease 447 
LD: limited disease 448 
RT: radiotherapy 449 
LDH: Lactate Dehydrogenase 450 
PS: performance status 451 
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 667 
 668 
Figure titles and legends: 669 
 670 
Figure 1: Overview of the inclusion process 671 
 672 
Figure 2: Correlations of FDG-SUVpeak, FLT-SUVpeak and ADCmedian in T-sites (a-c) and N-sites (d-e). FDG-673 
SUVpeak vs. FLT-SUVpeak were positive correlated in T-sites (a) and N-sites (d). FDG-SUVpeak vs. ADCmedian was 674 
not significantly correlated in T-sites (b), but significantly negative correlated in N-sites (e). ADCmedian vs. 675 
FLT-SUVpeak were neither correlated in T-sites (c) nor N-sites (f). Significant correlations (p <0.05) are 676 
marked with * 677 
 678 
25 
 
Figure 3: T-site (4-T) with high and heterogeneous FLT-uptake: FDG-PET (axial (a), coronal (b), sagittal (c)), 679 
FLT-PET (axial (d), coronal (e), sagittal (f)), and DW-MRI (transversal (g), coronal (h), sagittal (i)), and voxel-680 
by-voxel scatterplot of FDG-SUV vs. FLT-SUV (j) and FLT-SUV vs. ADC (k).  681 
This lesion was clearly detectable on FDG-PET (SUVpeak 22.7), detectable but very heterogeneous on FLT-PET 682 
(SUVpeak 11.5); and detectable on DW-MRI (ADCmedian 1.43 x10-3 mm2/s). The most metabolically active 683 
region (MTV70) was located caudally, whereas the most proliferative active region (PTV70) was located 684 
cranially within the tumor, thus MTV70 and PTV70 showed no overlap. The most water-diffusion restricted 685 
regions (DWTV50) were randomly distributed and overlapped partially with both MTV70 and PTV70. The 686 
voxel-by-voxel scatter plots (j-k), showed very weak overall correlations. This T-site had no change as 687 
response to chemotherapy. 688 
 689 
Figure 4: T-site (1-T) with low FLT-uptake: FDG-PET (axial (a), coronal (b), sagittal (c)), FLT-PET (axial (d), 690 
coronal (e), sagittal (f)), and DW-MRI (transversal (g), coronal (h), sagittal (i)), and voxel-by-voxel scatterplot 691 
of FDG-SUV vs. FLT-SUV (j).  692 
This T-site was clearly detectable on FDG-PET (SUVpeak 16.6); almost indistinguishable from background on 693 
FLT-PET (SUVpeak 1.6); and detectable on DW-MRI (ADCmedian 1.22 x10-3 mm2/s). The low tumor-to-694 
background ratio causes PTV70 to be less convincing, visually. MTV70 and DWTV50 had a partial ove rlap. 695 
The voxel-by-voxel scatter plot of FLT-SUV and FDG-SUV (j), showed an overall moderate positive 696 
correlation (r=0.50), but the very low FLT-SUVs should be noticed, and the correlation may be a result of 697 
perfusion to the region rather than a correlation between metabolism and (a very low) proliferation. Voxel-698 
by-voxel analysis was not feasible for FLT-SUV vs. ADC. This T-site had complete response to chemotherapy, 699 
and did not relapse during follow up. 700 
 701 
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Figure 5: N-site (12-N1): FDG-PET (axial (a), coronal (b), sagittal (c)), FLT-PET (axial (d), coronal (e), sagittal 702 
(f)), and DW-MRI (transversal (g), coronal (h), sagittal (i)), and voxel-by-voxel scatterplot of FDG-SUV vs. 703 
FLT-SUV (j), and FLT-SUV vs. ADC (k).  704 
This N-site were clearly detectable on FDG-PET (SUVpeak 11.6); FLT-uptake was the highest of all N-sites 705 
(SUVpeak 2.4); and detectable on DW-MRI (ADCmedian 1.56 x10-3 mm2/s). The most aggressive regions 706 
(MTV70, PTV70 and DWTV50) were located centrally within the tumor on all imaging modalities, and voxel-707 
by-voxel correlations were moderate for FDG-SUV vs. FLT-SUV (r=0.55) (j) and for FLT-SUV vs. ADC (r= -0.44) 708 
(k). This N-site progressed during chemotherapy. 709 
 710 
 711 
Figure 6: FDG-SUVpeak, FLT-SUVpeak, and ADCmedian in lesions with response vs. lesions with no change or 712 
progression. T-sites are shown in left panel (a-c) and N-sites in right panel (d-f). Note that no T-sites 713 
progressed during chemotherapy, and no N-sites had no change. FLT-SUVpeak was significantly different in T-714 
sites with response vs. no change (b) and in N-sites with response vs. progression (e). Three lesions with 715 
response had no signal on DW-MRI and are not included (c). Lesions that were not evaluated for response 716 
are included for completeness. NA*: response evaluation was not available due to atelectasis. NA**: The 717 
patient died prior to any response evaluation. 718 
 719 
 720 
Tables: 721 
 722 
Table 1: Patient characteristics and outcome. 723 
Pt 
no. 
age sex VALSG 
stage 
PS LDH Treatment Best 
response 
PFS 
(days) 
OS 
(days) 
Follow 
up 
(days) 
1 62 f ED 1 220 Car+eto x 6 CR 246 349  
27 
 
2 60 f ED 1 231 Car+eto x 6 
RT 30 Gy (bone 
metastases) 
PCI 
PR 194 320  
3 72 m ED 1 216 Car+eto x 6 PR 134 209  
4 77 m ED 1 354 Car+eto x 3 SD 90 114  
5 59 f ED/Relapse 2 267 Car+eto x 3 SD 220 220  
6 58 m LD 0 172 Cis+eto x 2, car+eto x 2 
Concomitant RT 60 Gy 
(RUL+mediastinum) 
PCI 
CR 155 
 
741 
7 76 m ED 3 1180 Eto x 1 
RT: Metastases (bone) 
NA* 47 47  
8 51 f ED 1 160 Car+eto x 6 
Sequential RT 30 Gy 
(mediastinum) 
PCI 
PR 243 
 
460 
9 60 f ED 1 264 Car+eto x 6 PR 195 321  
10 70 f ED/Relapse 1 173 Car+eto x 3 PR 124 347  
11 59 m ED 0 736 Car + eto x 6 
Sequential RT 30 Gy 
(Right 
lung+mediastinum) 
RT 30 Gy (metastases 
on the thoracic wall 
and on scull) 
SD 275 478  
12 74 m ED 0 NA Car + eto x 4 
Sequential RT 30 Gy 
(mediastinum, neck) 
PD 50 95  
f: female; m: male; VALSG stage: The Veteran’s administration Lung Study Group two stage classification 724 
scheme; ED: extensive disease; LD: limited disease; PS: WHO performance status; LDH: blood lactate 725 
dehydrogenase; NA: not available; car: carboplatin; eto: etoposide; RT: radiotherapy; PCI: prophylactic 726 
cranial irradiation; cis: cisplatin; RUL: right upper lobe; CR: complete response; PR: partial response; SD: 727 
stable disease; PD: progressive disease; PFS: progression free survival; OS: overall survival; * No response 728 
evaluation, as the patient died prior to evaluation. 729 
 730 
 731 
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Table 2: Malignant lesions: Location, FDG-SUVpeak, FLT-SUVpeak, ADCmedian; and outcome. 732 
LLL: left lower lobe; RUL: right upper lobe; 2R, 4R, etc.: lymph node stations; LUL: left upper lobe; RLL: right 733 
lower lobe; med: mediastinum; FDG: 18F-fluorodeoxy-glucose; PET: positron emission tomography; SUV: 734 
Pt 
no 
Lesio
n no 
Location FDG
-PET 
FLT-
PET 
DW-
MRI 
Lesion outcome Comments 
   SUV
peak 
SUV
peak 
ADCm
edian 
Lesion 
response 
Progressio
n (days) 
 
1 1-T LLL 16.5 1.6 1.22 response - 
 
 
1-N1 2R+4R 12.2 1.8 1.21 response - 
 
 
1-N2 10L+11L 13.4 1.5 0.90 response - 
 
 
1-N3 4L 15.5 1.9 0.88 response - 
 
 
1-N4 7 17.3 2.1 1.07 response 
  
 
1-M RUL 4.2 1.1 1.05 response - 
 
2 2-N 2R+4R+4L+7 NA 1.3 1.54 response 194 
 
3 3-T LLL+hilus sin 9.0 2.1 1.59 response - 
 
 
3-N1 8 8.1 1.6 1.96 response - 
 
 
3-N2 7 5.5 1.2 1.89 response - 
 
 
3-N3 4L+4R+5 8.0 1.3 1.39 response 134 
 
4 4-T LUL 22.7 11.5 1.43 no 
change 
90 
 
5 5-T Hilus dxt NA 2.6 1.74 no 
change 
- Previously irradiated 
6 6-T RLL 3.9 0.6 # response 155 
 
 
6-N 10-11R 6.2 1.3 2.09 response - 
 
7 7-T LUL+hilus+me
d 
8.3 4.0 NA NA NA No outcome evaluation as the 
patient died day 47  
7-M lymph node in 
left axil la 
5.2 1.9 NA NA NA No outcome evaluation as the 
patient died day 47 
8 8-T1 RUL+med 9.7 1.7 1.11 response - 
 
 
8-T2 RUL 2.0 0.6 # response - 
 
 
8-T3 RUL 2.2 0.7 # response - 
 
9 9-T1 LUL+med 12.1 1.7 1.74 response 195 
 
 
9-T2 LUL 3.7 1.3 1.01 response - 
 
10 10-T1 hilus sin+med NA 2.8 0.82 response 124 Previously irradiated  
10-T2 lingula NA 1.9 1.10 response - 
 
11 11-T1 RUL+med 11.8 3.0 1.15 no 
change 
275 
 
 
11-T2 RUL 4.4 1.0 0.76 NA - Response evaluation not 
possible due to atelectasis   
11-
M1 
Subcutis+os 
frontale 
8.9 2.3 1.03 no 
change 
- 
 
 
11-
M2 
Subcutis+costa 10.9 4.6 1.03 no 
change 
- 
 
12 12-T RUL 12.8 1.2 1.19 response - 
 
 
12-N1 4+7 11.6 2.4 1.56 progressi
on 
50 
 
 
12-N2 7+8 10.2 2.2 1.85 progressi
on 
50 
 
 
12-N3 10-11R 13.7 1.9 1.61 progressi
on 
50 
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standardized uptake value; FLT: 18F-fluorothymidine; DW: diffusion weighted; MRI: magnetic resonance 735 
imaging; ADC: apparent diffusion coefficient; NA: not available. 736 
 737 
 738 
 739 
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Figure 1 741 
 742 
 743 
  744 
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Figure 2 745 
 746 
T-sites N-sites 
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Figure 3 749 
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FDG-PET FLT-PET DW-MRI (b=800 s/mm2) 
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Figure 4 752 
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FDG-PET FLT-PET DW-MRI (b=800 s/mm2) 
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Figure 5 755 
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  757 
FDG-PET FLT-PET DW-MRI (b=800 s/mm2) 
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Figure 6 758 
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Supplementary Table 1: Scan data and time points 762 
Pt 
no. 
Baseline 
scan 
Project 
scan 
Days from 
baseline 
FDG-PET-
scan to 
FLT-
PET/MRI 
Days from 
treatment 
start to 
FLT-
PET/MRI 
FDG-PET scanner/model 
Software 
Reconstruction method 
FDG-
uptake 
interval 
in 
minutes 
FLT-uptake 
interval in 
minutes 
(cerebrum/thorax) 
1 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
16 1 
Philips medical 
system/Gemini TF TOF 64 
9.5.1  
BLOB-OS-TF 
85 56/71 
2 CT 
FLT-
PET/DW-
MRI 
 6 
 
 58/76 
3 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
14 2 
Philips medical 
system/Gemini TF TOF 64  
9.5.1  
BLOB-OS-TF 
72 58/76 
4 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
16 6 
Philips medical 
system/Gemini TF TOF 64  
9.5.1  
BLOB-OS-TF 
75 67/84 
5 CT 
FLT-
PET/DW-
MRI 
 1 
 
 66/83 
6 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
17 6 
Philips medical 
system/Gemini TF TOF 64  
9.5.1  
BLOB-OS-TF 
84 51/69 
7 
FDG-
PET/CT 
FLT-
PET/MRI 
(only T1 
MRI 
No 
contrast) 
7 1 
Siemens/somatom 
definition AS_mCT 
syngo.MI PET/CT 2012a 
PSF+TOF 2i21s 
60 58/79 
8 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
14 2 
Siemens/1094 
PET/CT 2009a 
PSF 3i21s 
64 62/84 
9 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
20 9 
Philips medical 
system/Gemini TF TOF 64  
9.5.1  
BLOB-OS-TF 
74 58/77 
10 CT 
FLT-
PET/DW-
MRI 
 3 
 
 56/73 
11 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
8 6 
Siemens/1094 
PET/CT 2009a 
PSF 3i21s 
62 54/82 
12 
FDG-
PET/CT 
FLT-
PET/DW-
MRI 
21 6 
GE medical 
systems/Discovery 710 
53.00 
QCFX 
63 55/72 
 763 
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Supplementary Table 2: PET- and MRI-parameters from malignant lesions. 764 
MTV41: metabolic tumor volume delineated with a threshold of 41% of SUVmax; SUV: standardized uptake 765 
value; PTV50: proliferative tumor volume delineated with a threshold of 50% of SUVmax; GTV: gross tumor 766 
volume; DWTV25: diffusion weighted tumor volume delineated on DW-MRI (b=800  s/mm2) using a 767 
threshold of 25% of maximum; ADC: apparent diffusion coefficient. 768 
* = PTV50 could not be distinguished from background uptake; # = Tumor not visible on MRI and/or DW-769 
MRI. 770 
Tumor volumes in cm2; ADC in 10-3 mm2/s 771 
  772 
Pt 
no. 
Lesion 
no. 
FDG-PET FLT-PET MRI DW-MRI Voxel-by-voxel 
correlation 
coefficient 
Comments 
  MTV
41 
SUVpeak PTV 
50 
SUVpeak GTV DWTV 
25 
ADCmedian r (FDG 
vs. FLT) 
r (FLT vs. 
DWI) 
 
1 1-T 23.5 16.5 * 1.6 45.1 21.3 1.22 0.50  
 
 
1-N1 9.8 12.2 * 1.8 17.4 13.5 1.21 0.03  
 
 
1-N2 24.3 13.4 * 1.5 33.9 30.7 0.90 0.42  
 
 
1-N3 23.7 15.5 * 1.9 29.2 27.6 0.88 0.03 0.41 
 
 
1-N4 17.4 17.3 * 2.1 13.6 13.5 1.07 -0.24 -0.01 
 
 
1-M 2.4 4.2 2.4 1.1 
 
4.5 1.05   
 
2 2-N NA NA * 1.3 120 105 1.54  0.08 
 
3 3-T 104 9.0 37.5 2.1 169 137 1.59  0.21 
 
 
3-N1 7.2 8.1 * 1.6 14.2 9.0 1.96  0.07 
 
 
3-N2 20.0 5.5 * 1.2 25.6 13.7 1.89  -0.18 
 
 
3-N3 27.8 8.0 * 1.3 49.9 24.3 1.39  -0.20 
 
4 4-T 224 22.7 17.6 11.5 273 193 1.43 0.10 -0.15 
 
5 5-T NA NA 18.7 2.6 10.4 17.0 1.74  -0.02 Previously irradiated. 
6 6-T 4.0 3.9 * 0.6 1.0 # #   
 
 
6-N 8.3 6.2 3.1 1.3 3.9 10.3 2.09   
 
7 7-T 94.2 8.3 15.3 4.0 149 NA NA 0.49    
7-M 3.7 5.2 4.9 1.9 
 
NA NA    
8 8-T1 51.4 9.7 * 1.7 57.7 58.9 1.11  0.32 Surrounding carcinomatosis included in 
the tumor volumes.  
8-T2 2.3 2.0 0.5 0.6 # # #   
 
 
8-T3 0.7 2.2 3.4 0.7 # # #   
 
9 9-T1 125 12.1 91.2 1.7 165 57.1 1.74  -0.03 Inseparable athelectasis included in GTV.  
9-T2 
 
3.7 5.0 1.3 5.3 3.2 1.01  0.42 
 
10 10-T1 NA NA 11.7 2.8 23.2 40.6 0.82  -0.54 Previously irradiated.  
10-T2 NA NA 3.8 1.9 3.5 5.6 1.10  -0.66 
 
11 11-T1 190 11.8 74.3 3.0 285 167 1.15 0.50 -0.01 
 
 
11-T2 1.2 4.4 1.9 1.0 2.6 2.6 0.76   
 
 
11-M1 18.6 8.9 25.0 2.3 22.1 24.2 1.03 0.45 0.12 
 
 
11-M2 280 10.9 135 4.6 307 200 1.03 0.62 -0.34 
 
12 12-T 15.7 12.8 15.5 1.2 20.2 10.5 1.19   
 
 
12-N1 12.3 11.6 11.1 2.4 13.2 14.5 1.56 0.55 -0.44 
 
 
12-N2 24.8 10.2 20.9 2.2 20.4 18.4 1.85 0.41 -0.16 
 
 
12-N3 21.4 13.7 19.5 1.9 22.6 18.2 1.61 0.60 -0.41 
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Supplementary Table 3: Comparison of PET- and MRI-parameters in lesions with response vs. no change 773 
or progression. Note that no T-sites had progression, and no N-sites had no change, therefore analyses of 774 
T-sites are performed as lesions with response vs. lesions with no change, and analyses of N -sites are 775 
performed as lesions with response vs. lesions with progression. Mean difference and p-value from 776 
independent t-test. Significant results are marked with *. 777 
 778 
 Imaging 
modality 
Parameter n (lesion with 
response + 
lesions with no 
change / 
progression) 
Mean (range)  
of lesions with 
response 
Mean (range)  
of lesions with no 
change/progression 
p  
T-sites FDG-PET FDG-SUVpeak 9+2 8.0 (2.0-16.5) 17.3 (11.8-22.7) 0.063  
MTV41 8+2 41 (0.7-126) 208 (191-225) 0.002*  
TLG41 8+2 312 (2-1067) 2410 (1583-3237) 0.006*  # 
FLT-PET FLT-SUVpeak 11+3 1.5 (0.6-2.8) 5.7 (2.6-11.5) 0.007*  # 
PTV50 8+3 21.1 (0.5-91.2) 36.9 (17.6-74.3) 0.472  
TLP50 9+3 35.5 (0-119) 120 (37-171) 0.029*  
DW-MRI DWTV25 8+3 41.7 (3.2-137) 126 (17.0-193) 0.067  
ADCmedian 8+3 1.22 (0.82-1.74) 1.44 (1.15-1.74) 0.315  
N-sites FDG-PET FDG-SUVpeak 8+3 10.8 (5.5-17.3) 11.8 (10.2-13.7) 0.585  
MTV41 8+3 17.3 (7.2-27.8) 19.5 (12.3-24.8) 0.684  
TLG41 8+3 140 (38-275) 168 (107-203) 0.644  
FLT-PET FLT-SUVpeak 9+3 1.6 (1.2-2.1) 2.2 (1.9-2.4) 0.013*  
PTV50 1+3 3.1 (3.1-3.1) 17.2 (11.1-20.9) 0.148  
TLP50 1+3 3.4 (3.4-3.4) 28.6 (21-36) 0.095  
DW-MRI DWTV25 9+3 27.5 (9.0-105) 17.0 (14.5-18.4) 0.573  
ADCmedian 9+3 1.44 (0.88-2.09) 1.67 (1.56-1.85) 0.416  
# Values are estimated from log-transformed data. 779 
 780 
 781 
  782 
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Supplementary Table 4: FLT-uptake in normal tissue. Values deviating from the reference interval are 783 
written in red. References from Cysouw et al. 784 
pt no. FLT-PET parameters  
Liver Blood pool Bone marrow  
SUVmax SUVpea
k 
SUVmea
n 
SUVmax SUVpeak SUVmean SUVmax SUVpea
k 
SUVmea
n 
1 9.4 8.1 7.4 1.4 1.2 1.1 2.1 1.7 1.6 
2 7.8* 5.8* 4.8* 0.9 0.8 0.7 1.4 1.2 1.1 
3 8.1 7.1 6.1 1.0 0.7 0.6 4.2 3.6 3.6 
4 2.5 2.1 1.8 0.8 0.7 0.6 3.4 2.8 2.5 
5 13.0 11.3 9.7 1.6 1.3 1.1 2.7 2.1 2.1 
6 2.3 2.0 1.6 0.8 0.7 0.6 4.8 4.0 3.9 
7 ¤ ¤ ¤ 0.8 0.7 0.6 13.4 11.3 11.3 
8 6.5 5.3 4.6 0.7 0.6 0.5 7.7 6.5 6.5 
9 7.5 6.7 4.8 0.8 0.7 0.6 3.6 2.5 2.6 
10 6.2 5.1 4.6 1.0 0.8 0.7 1.7 1.5 1.4 
11 2.8 2.8 1.3 0.7 0.7 0.5 3.9 3.0 3.0 
12 # # # 0.7 0.7 0.6 3.8 3.2 3.0 
Mean±SD 6.6±3.
9 
5.5±2.
9 
4.7±2.7 0.93±0.2
9 
0.80±0.2
2 
0.68±0.2
0 
4.4±3.
3 
3.6±2.
8 
3.6±2.8 
Referenc
e 
3.68-
8.17 
3.46-
7.46 
3.09-
6.45 
0.47-1.12 0.44-1.04 0.38-0.93 5.84-
12.54^ 
4.86-
11.36^ 
4.41-
9.74^ 
*fatty liver; ¤liver not included in frame; #large metastases in liver; ̂ reference for bone marrow was based 785 
on several vertebras. 786 
 787 
 788 
